Genetic Diversity in the Circumsporozoite Protein Gene of Plasmodium falciparum from Major Endemic Regions of Iran

*A Heidari¹, H Keshavarz¹, M Assmar², M Razavi², M Nateghpour¹, S Dittrich³, T Jelinek³

¹Dept. of Medical Parasitology, School of Public Health, Tehran University of Medical Sciences, Iran
²Dept. of Parasitology, Pasteur Institute of Iran, Tehran, Iran
³Berlin Institute of Tropical Medicine, Berlin-Germany

(Received 4 Jul 2005; revised 13 Dec 2005; accepted 11 Apr 2006)

Abstract
Circumsporozoite protein (CSP) is one of the stage specific antigens, which is used for the development of vaccines and to investigate the genetic diversity in Plasmodium falciparum malaria parasite. Polymerase chain reaction was used for typing of CSP genes on 67 positive falciparum malaria patients from Sistan and Baluchistan Province of Iran. Three fragments were detected for CSP gene. Twenty, 38 and 4 samples showed 700, 750 and 800 bp fragments, respectively. Sequences of some samples were aligned and compared with P.falciparum csp gene in gene bank. While the falciparum malaria endemic region of Iran is classified in low to moderate group but, extensive polymorphism was observed in the samples that could be taken into account in designing malaria vaccine.

Keywords: Circumsporozoite protein, Plasmodium falciparum, Malaria, Iran

Introduction
Malaria is one of the most important infectious diseases in the world. It causes 300-500 million clinical cases and 1.1-2.7 million deaths annually (1). Genetic diversity presented by P.falciparum field isolates and the occurrence of variant from of the parasite in different geographic area constitute one of the main obstacle to the design of a malaria vaccine (2, 3).

The invasive stage of the vertebrate host consists of sporozoites, which are injected by the mosquito vector during its blood meal (4). Circum Sporozoite Protein (CSP) encodes predominant protein found in the structure of the sporozoite (5). This protein causes immune response in human and is important candidate for development of malaria vaccine (6, 7). A vaccine against sporozoites would, if effective, prime the human immune system to kill sporozoites injected by the mosquito and prevent the subsequent stages responsible for the disease and transmission of the infection to others (4). The gene for the (CSP) of P.falciparum is comprised of two terminal regions that are not repetitive (5′ NR and 3′ NR), which embrace a central region (CR) of tandemly repeats (mostly between 40 and 50) which vary in size and relative position from one strain to another strain of P.falciparum (8). It encodes predominant protein that contains approximately 420 amino acids as deduced from the nucleotide sequence (9). PCR that detect low numbers of parasite in small sample volume has been used for detection of genetic diversity (10) and the geographical distribution of the various alleles of polymorphic genes of the P.falciparum (11, 12). The tribulations encountered in Sistan and Baluchistan Province are resistance of P.falciparum to drugs (13, 14) and that of vectors to insecticides, likewise importation of malaria mostly of P.falciparum kind originating from Afghanistan.

* Corresponding author: Tel: +98 21 8951392, E-mail: aliehsan2001@yahoo.com
immigrants and to some lesser extent, from Pakistan. Hence designing of efficient malaria vaccine is useful for control of *falciparum* malaria in this area.

Since there is no information about polymorphism of the gene encoding CSP vaccine candidate in south east of Iran, we investigated the diversity of the gene using PCR and some partial sequences from field isolates from Sistan and Baluchistan province.

**Materials and Methods**

**Study area and blood collection**  *falciparum* malaria is endemic in south and southeast of Iran. Sistan and Baluchistan province is located in the southeast endemic area of the country. A total of 12885 malaria cases were reported in 2004, 56% of these cases were reported from Sistan and Baluchistan that consisted 85% of total *falciparum* malaria (15).

This study involved 67 native individual aged between 2 and 45 yr. Fifty-six blood samples were collected from the Pishine area main region for endemic *falciparum* malaria of Iran and 11 samples from Iranshar area. Sample collection was carried out from May 2003 to December 2004. Patients with *P. falciparum* malaria attending the local malaria clinics and health centers were selected for the study. Native individuals without history of anti malaria treatment for the last month and written consent were required for inclusion in the study. Diagnosis of *P. falciparum* was confirmed by light microscopy on thick blood smear. Blood samples were collected in tubes containing anti coagulant solution, stored at 20 °C.

**Isolation of DNA and sequencing**  DNA was extracted from the blood sample by a modification in Claude-Leclerc method (16). Two hundred µl of blood was washed 3 times in phosphate-buff ed saline (PBS). The red blood cells were lysed by suspension in 100 mM NaCl, 10 mM EDTA, 45 µl of 10% SDS and 8 µl of RNase at 500 µg/ml. The mixture was incubated for 2 h at 37 °C. Then 10 µl of proteinase K at 10 mg/ml was added and the mixture was incubated for 2 h at 55 °C. Then DNA was isolated in 20 µl of sterile water.

We used a set of primers including 5′ (5′ ATAGTAGATCACTTGGAGA 3′) and 3′ (5′ GCATATTGTGACCTTGCCA3′) described by Wooden (17), to amplify the region corresponding to base pairs 203-861 of the sequence from the Sa1 strain (U20969). For amplification, two µl of DNA was used in total reaction volume of 26 µl containing 50 mM KCl; 1.5mM MgCl2; 125 µM of each dNTP; 1u of Taq and a pair of primers (0.33 µM each). This reaction was amplified for 35 cycles at 94 °C for 1 min, 58 °C for 2 min and 72 °C for 2 min. The PCR amplified gene fragments were electrophoresed on 1% agarose gels, stained with ethidium bromide and visualized under ultraviolet light.

The PCR products of 5 samples were purified using Qiaquick PCR purification Kit (Qiagen Company). Sequences of DNA were performed by MWG Biotech (Germany). The DNA and amino acid sequences were aligned using Blast of pubmed. Chi-square test was applied to calculate significance of the results.

**Results**

PCR was performed on 67 positive *falciparum* malaria patients. The sizes of the PCR product ranged from 700 to 800 bp (Fig.1). Three fragments (700, 750 and 800 bp) were detected for the CSP gene. Twenty-five (37.3%) samples showed 700 bp fragment, 38 (56.7%) and 4 (5.9%) samples 750 and 800 bp fragments, respectively. In the Pishin area, 36% of the fragments illustrated as 700 bp, 57% as 750 bp and 7% as 800 bp. In the Iranshar area, 45.5% of fragments were detected as 700 bp and 54.5% as 750 bp fragments, respectively. In the Pishin area, 36% of the fragments illustrated as 700 bp, 57% as 750 bp and 7% as 800 bp. In the Iranshar area, 45.5% of fragments were detected as 700 bp and 54.5% as 750 bp (Fig. 2). There was no significant difference in the prevalence of these fragments between the two areas. There was no significant association between sex, age, and distribution of fragments in the CSP gene.

Sequences of CSP gene from blood samples of 5 *falciparum* malaria patients were aligned and compared with *P. falciparum* CSP gene sequences from published data and gene bank.
The similarity in nucleotides within the CSP isolates varied from 83% to 97%. The similarity in nucleotides with Sal1 allele (U20969) was 85%, 98%, 88%, 94%, and 92% for IRI1, IRI2, IRI3, IRI4, and IRI5, respectively. The homology within CSP isolates with *P. falciparum* clone Ken 612 CSP gene (AF540457) was 86%, 99%, 88%, 95%, and 92% for IRI1, IRI2, IRI3, IRI4, and IRI5, respectively. The homology in CSP isolates with *P. falciparum* isolate 96 M320 (AB11607) was 86%, 99%, 88%, 95% and 92% for IRI1, IRI2, IRI3, IRI4, and IRI5, respectively.

**Fig. 1:** Gel photograph showing PCR amplified products of CSP from different *P. falciparum* infected isolates in Southeast of Iran. The DNA size marker is a 100 bp ladder shown on the left and right sides. Lane 11 is negative control.

**Fig. 2:** Distribution of variants of CSP in two regions of Iran
Discussion

Determination of polymorphism of the gene encoding the polymorphic loci CSP of *P. falciparum* would help us evaluate the potential of this protein as anti malarial vaccine. (18). Our genotyping results are less than those found in Orrisa, India are (5 alleles) (19), but more than those found in New Delhi in the same country (1 allele) (20). It seems that different number of alleles is found in various geographical regions. However, the values obtained are slightly inferior to those observed in Senegal (4 alleles) with a high rate of malaria transmission (16). However, in general, Iran is a hypo endemic country for malaria (21), but our finding shows polymorphism in major *falciparum* endemic region of Iran. It seems movement and migrating of people between the mentioned regions and neighboring countries (Pakistan and Afghanistan) may introduce different alleles of *P. falciparum* into in these regions of Iran. Multiple infections in these loci have not been shown, this finding agrees with studies in India and Senegal (16, 20). Of course, we have shown multiple infections in other genes such as Merozoites surface protein (MSP) 1 and MSP2 in these regions (22).

There was not significant association between distribution of fragments and two regions of study. It seems frequent travels between the mentioned regions is a reason for it. Sequencing results indicated that 5 distinct alleles for *P. falciparum* CSP were detected among these 5 randomly sequenced isolates. 83% to 97% homologies in the alignment between isolates of the study have indicated presence of synonymous and non-synonymous substitutions. Several (one to ten) nucleotide substitutions occurred before the region 5 of the central repeat between pairs of alleles, this finding agrees with a study on African isolates (23). Substitutions in the partial sequenced as compared to the previously published sequences of Sal1 isolate some amino acids in the region of 90 to 165 CSP genes (Fig. 3). The present study reported the variation in the selected vaccine candidate antigens in Iranian isolates of *P. falciparum* that could be taken into account in developing malaria vaccine.

Further population-based studies of sequences of other candidate antigen genes of *P. falciparum* will provide more information in this area for designing of malaria vaccine.
Acknowledgements
We would like to thank those individuals from the malaria endemic region of Iran, who kindly contributed to this study and are grateful to Mr Satvat, Mr Akbarzadeh, and Mr Seidzadeh for the assistance to sampling, Dr Edrissian, Dr Rezaai for their invaluable guidance’s and all staff of Institute of Tropical Medicine of Berlin. This study was supported financially by the Iranian Ministry of Health and the Institute of Tropical Medicine Berlin-Germany.

References


